The results of research studies conducted GDUFA initiatives provide new tools for FDA to evaluate generic drug equivalence.
Similar Posts
FDA Public Workshop: Future Needs for the Development of Interchangeable Products – 09/19/2025
The public meeting will be held on September 19, 2025, from 9 a.m. to 1 p.m. The meeting agenda, federal register notice, additional materials, and any other updates will also be posted to this website as they become available.USA LESS Co. is Recalling Rhino Choco VIP 10X Due to Undeclared Tadalafil
BROOKLYN, N.Y., Feb. 27, 2026 /PRNewswire/ — USALESS.COM is recalling its RHINO CHOCO VIP
10X, in 10 gr, 12 pc packages that come in a black cardboard box marked with UPC Code 724087947668 on the back and with an expiration date of 10/2027 stamped on the back. The product is sold in retail stores aFDA approves 1st drug for thymidine kinase 2 deficiency, a very rare mitochondrial disease
FDA approves 1st drug for thymidine kinase 2 deficiency, a very rare mitochondrial diseaseInformation for Consumers and Patients | Drugs
Drug Information for Patients and ConsumersFDA In Brief: Findings from Real-World Data Study Reveal Higher Risk of Hospitalization and Death Among Cancer Patients with COVID-19, Underscore Health Disparities
FDA and Syapse presented Real-World Data at the American Association of Clinical Research (AACR) COVID-19 and Cancer meeting. Findings from study reveal higher risk of hospitalization and death among cancer patients with COVID-19.FDA-TRACK: Prescription Drug User Fee Act Procedural Goals Summary
FDA-TRACK: Prescription Drug User Fee Act Procedural Goals Summary